NASDAQ:GTHX G1 Therapeutics (GTHX) Stock Forecast, Price & News $2.62 +0.09 (+3.56%) (As of 06/2/2023 ET) Add Compare Share Share Today's Range$2.55▼$2.6650-Day Range$2.46▼$3.1452-Week Range$2.38▼$17.49Volume569,510 shsAverage Volume906,012 shsMarket Capitalization$135.35 millionP/E RatioN/ADividend YieldN/APrice Target$16.60 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability G1 Therapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.83 Rating ScoreUpside/Downside533.6% Upside$16.60 Price TargetShort InterestHealthy6.04% of Shares Sold ShortDividend StrengthN/ASustainability-2.45Upright™ Environmental ScoreNews Sentiment0.20Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.44) to ($1.05) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.25 out of 5 starsMedical Sector338th out of 983 stocksPharmaceutical Preparations Industry153rd out of 486 stocks 3.4 Analyst's Opinion Consensus RatingG1 Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $16.60, G1 Therapeutics has a forecasted upside of 533.6% from its current price of $2.62.Amount of Analyst CoverageG1 Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted6.04% of the outstanding shares of G1 Therapeutics have been sold short.Short Interest Ratio / Days to CoverG1 Therapeutics has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in G1 Therapeutics has recently decreased by 5.74%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldG1 Therapeutics does not currently pay a dividend.Dividend GrowthG1 Therapeutics does not have a long track record of dividend growth. Previous Next 3.8 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreG1 Therapeutics has received a 49.69% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Detoxifying agents for antineoplastic treatment (V03AF)" and "Clinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for G1 Therapeutics is -2.45. Previous Next 2.3 News and Social Media Coverage News SentimentG1 Therapeutics has a news sentiment score of 0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for G1 Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 12 people have searched for GTHX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows3 people have added G1 Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, G1 Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.23% of the stock of G1 Therapeutics is held by insiders.Percentage Held by Institutions53.13% of the stock of G1 Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for G1 Therapeutics are expected to grow in the coming year, from ($1.44) to ($1.05) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of G1 Therapeutics is -0.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of G1 Therapeutics is -0.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioG1 Therapeutics has a P/B Ratio of 3.01. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About G1 Therapeutics (NASDAQ:GTHX) StockG1 Therapeutics, Inc. engages in the development of small molecule therapeutics for the treatment of patients with cancer. Its products pipeline includes trilaciclib, rintodestrant, and lerociclib. The company was founded by Kwok-Kin Wong and Norman E. Sharpless on May 19, 2008 and is headquartered in Research Triangle Park, NC.Read More Receive GTHX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for G1 Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address GTHX Stock News HeadlinesJune 1, 2023 | americanbankingnews.comG1 Therapeutics, Inc. (NASDAQ:GTHX) Sees Large Drop in Short InterestMay 31, 2023 | americanbankingnews.comGlobeStar Therapeutics (OTCMKTS:GSTC) versus G1 Therapeutics (NASDAQ:GTHX) Head to Head ComparisonJune 4, 2023 | Legacy Research (Affiliate) (Ad)Sell Every Stock, Except ONE (Ticker Revealed)We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.May 22, 2023 | finance.yahoo.comG1 Therapeutics Announces Appointment of Monica Thomas as General CounselMay 16, 2023 | finance.yahoo.comNew Study Confirms Consistent Risk of Myelosuppression Across All Patients Receiving Chemotherapy for Small Cell Lung CancerMay 15, 2023 | americanbankingnews.comG1 Therapeutics, Inc. (NASDAQ:GTHX) Receives Average Rating of "Moderate Buy" from AnalystsMay 10, 2023 | markets.businessinsider.comBTIG Sticks to Its Buy Rating for G1 Therapeutics (GTHX)May 10, 2023 | markets.businessinsider.comH.C. Wainwright Keeps Their Buy Rating on G1 Therapeutics (GTHX)June 4, 2023 | Legacy Research (Affiliate) (Ad)Sell Every Stock, Except ONE (Ticker Revealed)We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.May 10, 2023 | msn.comG1 Therapeutics trilaciclib cuts adverse events linked to Trodelvy in breast cancer patientsMay 10, 2023 | finance.yahoo.comNew Results from Phase 2 Trial Confirm Benefit of Trilaciclib in Reducing Adverse Events Related to an Antibody Drug Conjugate (ADC)May 9, 2023 | americanbankingnews.comG1 Therapeutics, Inc. to Post Q2 2023 Earnings of $0.08 Per Share, HC Wainwright Forecasts (NASDAQ:GTHX)May 9, 2023 | americanbankingnews.comWedbush Weighs in on G1 Therapeutics, Inc.'s Q2 2023 Earnings (NASDAQ:GTHX)May 8, 2023 | finance.yahoo.comAnalysts Just Published A Bright New Outlook For G1 Therapeutics, Inc.'s (NASDAQ:GTHX)May 5, 2023 | finance.yahoo.comG1 Therapeutics First Quarter 2023 Earnings: Beats ExpectationsMay 4, 2023 | msn.comRaymond James Maintains G1 Therapeutics (GTHX) Outperform RecommendationMay 4, 2023 | msn.comHC Wainwright & Co. Reiterates G1 Therapeutics (GTHX) Buy RecommendationMay 3, 2023 | finance.yahoo.comRTP drug developer adds $30M to extend cash runwayMay 3, 2023 | msn.comRecap: G1 Therapeutics Q1 EarningsMay 3, 2023 | finance.yahoo.comG1 Therapeutics Provides First Quarter 2023 Financial Results and Operational HighlightsMay 2, 2023 | msn.comEarnings Preview: G1 TherapeuticsMay 1, 2023 | americanbankingnews.comG1 Therapeutics (GTHX) Set to Announce Earnings on WednesdayApril 26, 2023 | finance.yahoo.comG1 Therapeutics to Release First Quarter 2023 Financial Results and Provide Business Update on May 3, 2023April 23, 2023 | americanbankingnews.comG1 Therapeutics (NASDAQ:GTHX) Earns Buy Rating from Needham & Company LLCApril 19, 2023 | msn.comNeedham Reiterates G1 Therapeutics (GTHX) Buy RecommendationApril 19, 2023 | markets.businessinsider.comWhat 6 Analyst Ratings Have To Say About G1 TherapeuticsApril 18, 2023 | finance.yahoo.comG1 Therapeutics, Inc.'s (NASDAQ:GTHX) Shares Lagging The Industry But So Is The BusinessSee More Headlines GTHX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GTHX Company Calendar Last Earnings5/03/2023Today6/03/2023Next Earnings (Estimated)8/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:GTHX CUSIPN/A CIK1560241 Webwww.g1therapeutics.com Phone(919) 213-9835Fax919-741-5830Employees148Year FoundedN/APrice Target and Rating Average Stock Price Forecast$16.60 High Stock Price Forecast$25.00 Low Stock Price Forecast$10.00 Forecasted Upside/Downside+533.6%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($2.77) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-147,560,000.00 Net Margins-219.66% Pretax Margin-216.69% Return on Equity-222.92% Return on Assets-71.63% Debt Debt-to-Equity Ratio1.72 Current Ratio4.57 Quick Ratio4.11 Sales & Book Value Annual Sales$51.30 million Price / Sales2.64 Cash FlowN/A Price / Cash FlowN/A Book Value$0.87 per share Price / Book3.01Miscellaneous Outstanding Shares51,660,000Free Float47,409,000Market Cap$135.35 million OptionableOptionable Beta1.92 Key ExecutivesJack BaileyPresident, Chief Executive Officer & DirectorTerry L. MurdockChief Operating OfficerJohn UmsteadChief Financial OfficerRajesh K. MalikChief Medical OfficerMonica ThomasChief Compliance Officer & General CounselKey CompetitorsMilestone PharmaceuticalsNASDAQ:MISTProQR TherapeuticsNASDAQ:PRQREvofem BiosciencesNASDAQ:EVFMGreenwich LifeSciencesNASDAQ:GLSIEsperion TherapeuticsNASDAQ:ESPRView All CompetitorsInsiders & InstitutionsAmeriprise Financial Inc.Bought 33,395 shares on 5/22/2023Ownership: 0.290%JPMorgan Chase & Co.Bought 113,904 shares on 5/18/2023Ownership: 4.161%State Street CorpBought 18,430 shares on 5/16/2023Ownership: 0.384%Squarepoint Ops LLCSold 21,859 shares on 5/16/2023Ownership: 0.053%Susquehanna International Group LLPSold 10,900 shares on 5/16/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions GTHX Stock - Frequently Asked Questions Should I buy or sell G1 Therapeutics stock right now? 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for G1 Therapeutics in the last twelve months. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" GTHX shares. View GTHX analyst ratings or view top-rated stocks. What is G1 Therapeutics' stock price forecast for 2023? 6 Wall Street analysts have issued 1-year price targets for G1 Therapeutics' stock. Their GTHX share price forecasts range from $10.00 to $25.00. On average, they expect the company's stock price to reach $16.60 in the next twelve months. This suggests a possible upside of 533.6% from the stock's current price. View analysts price targets for GTHX or view top-rated stocks among Wall Street analysts. How have GTHX shares performed in 2023? G1 Therapeutics' stock was trading at $5.43 at the start of the year. Since then, GTHX stock has decreased by 51.7% and is now trading at $2.62. View the best growth stocks for 2023 here. Are investors shorting G1 Therapeutics? G1 Therapeutics saw a decrease in short interest in the month of May. As of May 15th, there was short interest totaling 3,120,000 shares, a decrease of 5.7% from the April 30th total of 3,310,000 shares. Based on an average trading volume of 938,200 shares, the days-to-cover ratio is currently 3.3 days. View G1 Therapeutics' Short Interest. When is G1 Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 2nd 2023. View our GTHX earnings forecast. How were G1 Therapeutics' earnings last quarter? G1 Therapeutics, Inc. (NASDAQ:GTHX) released its quarterly earnings results on Wednesday, May, 3rd. The company reported ($0.53) earnings per share for the quarter, beating analysts' consensus estimates of ($0.64) by $0.11. The company had revenue of $12.95 million for the quarter, compared to the consensus estimate of $10.54 million. G1 Therapeutics had a negative net margin of 219.66% and a negative trailing twelve-month return on equity of 222.92%. What ETFs hold G1 Therapeutics' stock? ETFs with the largest weight of G1 Therapeutics (NASDAQ:GTHX) stock in their portfolio include Invesco Nasdaq Future Gen 200 ETF (QQQS). What other stocks do shareholders of G1 Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other G1 Therapeutics investors own include Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), ImmunoGen (IMGN), Inovio Pharmaceuticals (INO), Johnson & Johnson (JNJ), Gilead Sciences (GILD), Kadmon (KDMN), VBI Vaccines (VBIV), Novavax (NVAX) and Pfizer (PFE). When did G1 Therapeutics IPO? (GTHX) raised $101 million in an initial public offering on Wednesday, May 17th 2017. The company issued 6,300,000 shares at $15.00-$17.00 per share. J.P. Morgan and Cowen and Company acted as the underwriters for the IPO and Needham & Company and Wedbush PacGrow were co-managers. What is G1 Therapeutics' stock symbol? G1 Therapeutics trades on the NASDAQ under the ticker symbol "GTHX." Who are G1 Therapeutics' major shareholders? G1 Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Fisher Asset Management LLC (5.27%), JPMorgan Chase & Co. (4.16%), BlackRock Inc. (2.68%), FMR LLC (1.87%), Raymond James & Associates (1.45%) and Bank of America Corp DE (1.17%). Insiders that own company stock include Andrew Perry, Glenn P Muir, James S Hanson, Jennifer K Moses, John E (Jack) Jr Bailey, Mark A Velleca, Mark A Velleca, Rajesh Malik, Seth Rudnick and Terry L Murdock. View institutional ownership trends. How do I buy shares of G1 Therapeutics? Shares of GTHX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is G1 Therapeutics' stock price today? One share of GTHX stock can currently be purchased for approximately $2.62. How much money does G1 Therapeutics make? G1 Therapeutics (NASDAQ:GTHX) has a market capitalization of $135.35 million and generates $51.30 million in revenue each year. The company earns $-147,560,000.00 in net income (profit) each year or ($2.77) on an earnings per share basis. How many employees does G1 Therapeutics have? The company employs 148 workers across the globe. How can I contact G1 Therapeutics? G1 Therapeutics' mailing address is 700 Park Offices Drive Suite 200, Research Triangle Park NC, 27709. The official website for the company is www.g1therapeutics.com. The company can be reached via phone at (919) 213-9835, via email at jmacdonald@g1therapeutics.com, or via fax at 919-741-5830. This page (NASDAQ:GTHX) was last updated on 6/4/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding G1 Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.